CAMBRIDGE, Mass., May 28, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the ...

The Cambridge drugmaker was a founding member of the nonprofit OUTbio in 2015 and has also had an affinity group called the Sexuality And Gender Alliance since 2018. Mass. companies display their ...

The court held that Alnylam had acted as its own lexicographer in defining the term “branched alkyl” in its patent specifications and that definition foreclosed Alnylam’s infringement ...

On June 2, H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his price target from $400 to $500. His bullish view reflects ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

On Tuesday, H.C. Wainwright analysts reiterated their Buy rating and $500 price target for Alnylam Pharmaceuticals stock (NASDAQ: NASDAQ: ALNY).This decision follows a recent fireside chat with ...

On Thursday, JPMorgan (NYSE: JPM) increased its price target for Alnylam Pharmaceuticals shares, now aiming for a $330.00 valuation. The biopharmaceutical company, traded under (NASDAQ: ALNY), ...

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler ...

On Thursday, JPMorgan (NYSE: JPM) reaffirmed its optimistic stance on Alnylam Pharmaceuticals (NASDAQ: ALNY), maintaining an Overweight rating and a price target of $330.00.According to InvestingPro ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...